Literature DB >> 19957198

Association between interleukin-6 gene promoter -572C/G polymorphism and the risk of sporadic Alzheimer's disease.

Mei-xia He1, Wan-li Yang, Ming-ming Zhang, Ya-jun Lian, Hai-ying Hua, Jin-sheng Zeng, Li-rong Zhang.   

Abstract

Inflammation is a key component of Alzheimer's disease (AD), and we have examined the effect of two polymorphisms (-174G/C and -572C/G) in the promoter of the inflammatory cytokine interleukin-6 (IL-6) gene on risk of AD in 318 AD patients. Significant differences in genotype and allele frequencies of -572C/G IL-6 promoter polymorphism were observed between AD patients and controls. The GG genotype was associated with a decreased risk of developing AD (OR 0.423, 95% CI 0.200-0.894). Similarly, logistic regression analysis revealed that G allele was a protective factor for AD (OR 0.732, 95% CI 0.567-0.945). For -174G/C variability, no C variability was found in all the subjects. The frequency of the IL-6 -174G/C promoter polymorphism is very low or no variability in Henan Han population. The -572C/G polymorphism of IL-6 gene promoter region is associated with AD, and G allele is an independent protective factor for AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19957198     DOI: 10.1007/s10072-009-0199-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

Review 1.  Problems of reporting genetic associations with complex outcomes.

Authors:  Helen M Colhoun; Paul M McKeigue; George Davey Smith
Journal:  Lancet       Date:  2003-03-08       Impact factor: 79.321

Review 2.  Inflammation and Alzheimer's disease: mechanisms and therapeutic strategies.

Authors:  P S Aisen
Journal:  Gerontology       Date:  1997       Impact factor: 5.140

3.  C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance.

Authors:  Marina Cardellini; Lucia Perego; Monica D'Adamo; Maria Adelaide Marini; Cristina Procopio; Marta Letizia Hribal; Francesco Andreozzi; Simona Frontoni; Maurizio Giacomelli; Michele Paganelli; Antonio E Pontiroli; Renato Lauro; Franco Folli; Giorgio Sesti
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

4.  Association between an interleukin-6 promoter and 3' flanking region haplotype and reduced Alzheimer's disease risk in a German population.

Authors:  M Bagli; A Papassotiropoulos; M Knapp; F Jessen; M Luise Rao; W Maier; R Heun
Journal:  Neurosci Lett       Date:  2000-04-07       Impact factor: 3.046

5.  Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese.

Authors:  Lie-Ying Fan; Xiao-Qing Tu; Ye Zhu; Thomas Pfeiffer; Ralph Feltens; Winfried Stoecker; Ren-Qian Zhong
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

6.  Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases.

Authors:  Nobuto Shibata; Tohru Ohnuma; Tadashi Takahashi; Hajime Baba; Takuya Ishizuka; Mieko Ohtsuka; Akira Ueki; Masatsugu Nagao; Heii Arai
Journal:  Am J Med Genet       Date:  2002-05-08

7.  Association of interleukin-1 gene polymorphisms with dementia in a community-based sample: the Honolulu-Asia Aging Study.

Authors:  Berran Yucesoy; Rita Peila; Lon R White; Kim Ming Wu; Victor J Johnson; Michael L Kashon; Michael I Luster; Lenore J Launer
Journal:  Neurobiol Aging       Date:  2005-04-07       Impact factor: 4.673

8.  Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population.

Authors:  Caroline M L Chapman; John P Beilby; Steve E Humphries; Lyle J Palmer; Peter L Thompson; Joseph Hung
Journal:  Eur Heart J       Date:  2003-08       Impact factor: 29.983

Review 9.  Deciphering the molecular basis of memory failure in Alzheimer's disease.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  Neuron       Date:  2004-09-30       Impact factor: 17.173

10.  Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis.

Authors:  Monika Buraczynska; Lucyna Jozwiak; Piotr Ksiazek; Ewa Borowicz; Piotr Mierzicki
Journal:  Transl Res       Date:  2007-05-23       Impact factor: 7.012

View more
  7 in total

1.  Adult neurogenesis and neurodegenerative diseases: A systems biology perspective.

Authors:  Emrin Horgusluoglu; Kelly Nudelman; Kwangsik Nho; Andrew J Saykin
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-02-16       Impact factor: 3.568

Review 2.  Inflammatory Cytokines and Alzheimer's Disease: A Review from the Perspective of Genetic Polymorphisms.

Authors:  Fan Su; Feng Bai; Zhijun Zhang
Journal:  Neurosci Bull       Date:  2016-08-27       Impact factor: 5.203

3.  Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer's disease.

Authors:  Shih-Yuan Chen; Ta-Fu Chen; Liang-Chuan Lai; Jen-Hau Chen; Yu Sun; Li-Li Wen; Ping-Keung Yip; Yi-Min Chu; Yen-Ching Chen
Journal:  J Neuroinflammation       Date:  2012-01-24       Impact factor: 8.322

4.  IL-6-174 G/C and -572 C/G polymorphisms and risk of Alzheimer's disease.

Authors:  Hui-Ping Qi; Zheng-Yi Qu; Shu-Rong Duan; Shu-Qin Wei; Shi-Rong Wen; Sheng Bi
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

5.  The association between sex-related interleukin-6 gene polymorphisms and the risk for cerebral palsy.

Authors:  Dan Bi; Mingjie Chen; Xiaoli Zhang; Honglian Wang; Lei Xia; Qing Shang; Tongchuan Li; Dengna Zhu; Klas Blomgren; Lin He; Xiaoyang Wang; Qinghe Xing; Changlian Zhu
Journal:  J Neuroinflammation       Date:  2014-06-06       Impact factor: 8.322

Review 6.  Interleukin-6, a major cytokine in the central nervous system.

Authors:  María Erta; Albert Quintana; Juan Hidalgo
Journal:  Int J Biol Sci       Date:  2012-10-25       Impact factor: 6.580

7.  Panel of Genetic Variations as a Potential Non-invasive Biomarker for Early Diagnosis of Alzheimer's Disease.

Authors:  Suk Ling Ma; Linda Chiu Wa Lam
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-08-31       Impact factor: 2.582

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.